# OnCo record david-gershenson (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/david-gershenson/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "david-gershenson" ;
  schema:name "David M. Gershenson"@en ;
  schema:description "Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it."@en ;
  schema:url <https://onco.cc/people/david-gershenson/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  onco:tag "ovarian", "gynaecological", "trialist" ;
  schema:jobTitle "Gynaecologic oncologist, MD Anderson Cancer Center" ;
  schema:sameAs <https://orcid.org/0000-0001-9712-2140> ;
  onco:cancers <https://onco.cc/cancers/low-grade-serous-ovarian-cancer/>, <https://onco.cc/cancers/ovarian/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022/>, <https://onco.cc/key-papers/paper-gershenson-hormonal-maintenance-lgsoc-jco-2017/> ;
  schema:affiliation <https://onco.cc/institutions/md-anderson/> .